Accessibility Menu
Xenetic Biosciences logo

Xenetic Biosciences(NASDAQ) XBIO

Market Cap$5.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-95%
1 Year-31%
1 Month-15%
$2.44
-2.4%
-0.06Today
Xenetic Biosciences last closing stock price
MetricPriceDate
Last closeUSD 2.502026-07-28
Xenetic Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.41%USD 2.702026-07-21
1 month-15.11%USD 2.952026-06-26
3 month-16.67%USD 3.002026-04-29
Year to date+15.21%USD 2.172025-12-31
1 year-31.35%USD 3.642025-07-28
3 year-33.51%USD 3.762023-07-28
5 year-95.28%USD 53.002021-07-29
Since inception-99.99%USD 31,680.042014-01-24

Xenetic Biosciences Financials at a Glance

Market Cap

$5.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.19M

Net Income (TTM)

-$2.23M

EPS (TTM)

-$1.23

P/E Ratio

-2.03

Dividend

$0.00

Beta (Volatility)

0.86 (Low)

Price

$2.44

Volume

1,602.33

Open

$2.53

Previous Close

$2.50

Daily Range

$2.40 - $2.53

52-Week Range

$1.90 - $13.93

Estimated Earnings Date

Aug 7, 2026

XBIO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xenetic Biosciences

Xenetic Biosciences develops new cancer treatment technologies for patients with hard-to-treat tumors. Its main products help improve how existing cancer drugs work and deliver medicines more effectively. The company’s work aims to support doctors and researchers treating aggressive cancers.

What’s in the Xenetic Toolbox?

  • DNase Technology: Enzyme-based therapy in development, designed to help existing cancer treatments work better, especially for pancreatic and solid tumors. Targets hospitals and research centers.
  • XCART Platform: Personalized cell therapy for B-cell lymphomas, a type of blood cancer. Focuses on patients with limited treatment options.
  • PolyXen Platform (100% of revenue): Drug delivery system licensed to partners, improving how medicines stay in the body. Used by pharmaceutical companies.

Growth Moves: Xenetic’s Expansion Playbook

  • Signed royalty agreement with Takeda for PolyXen technology, ongoing since before 2023.
  • Formed research partnerships with Scripps Research and University of Virginia for DNase program in 2024-2025.
  • Manufacturing partnership with Catalent Pharma Solutions for clinical-grade DNase production, active in 2025.
  • Collaborations with Serum Institute of India, PJSC Pharmsynthez, and SynBio to expand technology reach.

Why Xenetic Stands Out (Without the Lab Coat)

Xenetic’s business model relies on licensing its technology to larger partners, generating steady royalty income. Its focus on DNase technology addresses a unique cancer mechanism, aiming to boost the effectiveness of other treatments. The company’s lean structure and external collaborations help manage costs and speed up research.

Five Things You Need to Know

  • Q2 2025 revenue was $589,897, down 18.8% from Q2 2024.
  • All revenue in 2025 came from PolyXen royalties via Takeda.
  • Q2 2025 net loss was $688,703, a 45.9% improvement year-over-year.
  • Cash balance was $4.8 million as of June 30, 2025.
  • Operating expenses fell 36.3% in Q2 2025 compared to Q2 2024.

Bottom Line

Xenetic has shifted from product sales to a royalty-based model, focusing on cancer research partnerships. Its streamlined approach and external collaborations help manage risk and support ongoing innovation.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2

CEO

James F. Parslow, MBA, CPA

Website

www.xeneticbio.com

Headquarters

Framingham, MA 01701, US

XBIO Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-75.05%

Net Income Margin

-70.03%

Return on Equity

-39.28%

Return on Capital

-38.33%

Return on Assets

-28.25%

Earnings Yield

-49.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.29M

Volume

1.60K

Avg. Volume

16.88K

Financials (TTM)

Gross Profit

$3.19M

Operating Income

-$2.39M

EBITDA

-$2.23M

Operating Cash Flow

-$1.82M

Capital Expenditure

-$6.00

Free Cash Flow

-$1.82M

Cash & ST Invst.

$7.35M

Total Debt

$0.00

Xenetic Biosciences Performance Analysis

Xenetic Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,706,92547.1%
20232023-12-31USD 2,539,98648.8%
20242024-12-31USD 2,500,284-1.6%
20252025-12-31USD 2,976,41119.0%
Xenetic Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-0.6%
Q32025-09-3074.1%
Q42025-12-31-25.4%
Q12026-03-315.3%
Xenetic Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.61-16.1%
20232023-12-31USD -2.71-41.3%
20242024-12-31USD -2.57-5.0%
20252025-12-31USD -1.58-38.7%
Xenetic Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3023.7%
Q32025-09-3026.7%
Q42025-12-3124.2%
Q12026-03-3120.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$806.92K

+36.0%

Gross Profit

$806.92K

+36.0%

Gross Margin

100.00%

N/A

Market Cap

$5.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.86M

N/A

Employees

2

N/A

Net Income

-$456.38K

+49.5%

EBITDA

-$456.38K

+49.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$7.35M

+42.3%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-28.25%

N/A

Return on Invested Capital

-34.45%

N/A

Free Cash Flow

-$536.38K

+46.5%

Operating Cash Flow

-$536.38K

+46.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QLGNQualigen Therapeutics, Inc.
$3.21+5.59%
SNGXSoligenix, Inc.
$0.37+1.02%
TTNPTitan Pharmaceuticals, Inc.
$2.34-11.36%
ENSCEnsysce Biosciences, Inc.
$0.25+0.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.32-0.08%
INTCIntel
$83.69-0.03%
NVDANvidia
$191.87-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$58.86-0.04%

Questions About XBIO

What is the current price of Xenetic Biosciences?

Xenetic Biosciences is trading at $2.48 per share.

What is the 52-week range for Xenetic Biosciences?

Over the past 52 weeks, Xenetic Biosciences has traded between $1.90 and $13.93.

How much debt does Xenetic Biosciences have?

As of the most recent reporting period, Xenetic Biosciences reported total debt of $0.00.

How much cash does Xenetic Biosciences have on hand?

Xenetic Biosciences reported $7.35M in cash and cash equivalents in its most recent financial results.

What is Xenetic Biosciences’s dividend yield?

Xenetic Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services